In vitro and in vivo studies conducted by Tse et al. (2008) were the first to show the inhibitory effect of navitoclax on anti-apoptotic proteins of the BCL-2 family for various tumor therapies including SCLC. Here, BCL2 is linked to small cell lung carcinoma.